» Articles » PMID: 16782914

Detection of Occult Lymph Node Metastases in Locally Advanced Node-negative Prostate Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2006 Jun 20
PMID 16782914
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study was to determine the incidence and clinical significance of occult metastases in the lymph nodes of patients with prostate cancer originally considered node negative by routine histologic evaluation.

Methods: Two hundred seventy four patients with pT3 prostate carcinoma treated by radical prostatectomy and bilateral lymph node dissection were included in this study. One hundred eighty patients were staged node negative (N0), while 94 patients were lymph node positive (N+), based on routine histologic evaluation. All lymph nodes from the 180 N0 patients were evaluated for occult metastases by immunohistochemistry using antibodies to cytokeratins and, if positive, prostate-specific antigen. Recurrence and overall survival were compared among patients with occult tumor cells (OLN+), with patients whose lymph nodes remained negative (OLN-), and with the 94 N+ patients.

Results: A total of 3,914 lymph nodes were evaluated from 180 N0 patients (average, 21.7 lymph nodes per patient). Occult tumor cells were found in 24 of 180 patients (13.3%). The presence of OLN+ was significantly associated with increased recurrence and decreased survival compared with OLN- patients (P < .001 and P = .019, respectively; relative risk of recurrence, 2.27; relative risk of death 2.07, respectively). The presence of occult lymph node metastases was an independent predictor of recurrence and death in a multivariable analysis. The outcome for patients with OLN+ disease was similar to that for patients with N+ disease.

Conclusion: The detection of occult lymph node metastases in patients with pT3N0 prostate cancer identifies those with significantly increased risk of prostate cancer recurrence and death.

Citing Articles

Lymphatic system regulation of anti-cancer immunity and metastasis.

Lei P, Fraser C, Jones D, Ubellacker J, Padera T Front Immunol. 2024; 15:1449291.

PMID: 39211044 PMC: 11357954. DOI: 10.3389/fimmu.2024.1449291.


An artificial intelligence model for detecting pathological lymph node metastasis in prostate cancer using whole slide images: a retrospective, multicentre, diagnostic study.

Wu S, Wang Y, Hong G, Luo Y, Lin Z, Shen R EClinicalMedicine. 2024; 71:102580.

PMID: 38618206 PMC: 11015342. DOI: 10.1016/j.eclinm.2024.102580.


Relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy.

Rodrigues Pessoa R, Nabavizadeh R, Shah P, Frank I, Tollefson M, Sharma V Prostate Cancer Prostatic Dis. 2023; 27(4):674-679.

PMID: 37714961 DOI: 10.1038/s41391-023-00724-9.


Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy.

Ozdemir B, Arnold N, Fleischmann A, Hensel J, Klima I, Kruithof-de Julio M Eur Urol Open Sci. 2022; 44:1-10.

PMID: 36185585 PMC: 9520506. DOI: 10.1016/j.euros.2022.07.005.


The survival benefit of different lymph node yields in radical prostatectomy for pN1M0 prostate cancer patients: Implications from a population-based study.

Hu J, Yu Y, Liu W, Zhong J, Zhou X, Xi H Front Oncol. 2022; 12:953069.

PMID: 36033541 PMC: 9404339. DOI: 10.3389/fonc.2022.953069.